Rubicon Research Limited (NSE:RUBICON)

Market Cap	129.25B
Revenue (ttm)	15.98B +87.2%
Net Income	2.06B +126.6%
EPS	13.03 +120.6%
Shares Out	164.75M
PE Ratio	60.19
Forward PE	42.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,371
Average Volume	243,288
Open	780.70
Previous Close	780.70
Day's Range	768.55 - 795.50
52-Week Range	570.75 - 822.00
Beta	n/a
RSI	67.97
Earnings Date	Feb 3, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ...

• Industry: Pharmaceutical Preparations
• Founded: 1999
• Employees: 903
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: RUBICON

Financial Performance

In fiscal year 2025, Rubicon Research's revenue was 12.84 billion, an increase of 50.40% compared to the previous year's 8.54 billion. Earnings were 1.34 billion, an increase of 47.63%.